menu

TAG: CERES NANO

Press Release – July 2, 2020   ​New preprint demonstrates a rapid and versatile method for improving detection of SARS-CoV-2

Ceres Nanosciences and its collaborators at George Mason University have developed a Nanotrap® particle method that significantly improves detection of SARS-CoV-2. In a preprint posted on June 25, 2020, the teams describe how Nanotrap particles enable a rapid method for capturing and concentrating heat-inactivated and infectious SARS-CoV-2.  The simple method described in the preprint takes as little as 10 minutes to prepare SARS-CoV-2 RNA for downstream testing and obviates the need for commercial nucleic acid extraction kits. Using contrived samples with heat-inactivated and infectious SARS-CoV-2, the authors demonstrated significant (5- to 25-fold) improvements in real-time RT-PCR detection of the virus...

READ MORE
Ceres Nanosciences Receives $225,000 NIH SBIR Phase I Grant to Improve Serum Quality for Cell and Tissue Engineering

MANASSAS, Va. — January 31, 2020 — Ceres Nanosciences, Inc. (Ceres) today announced it has been awarded a $225,000 Phase I SBIR grant from the NIH to apply the Nanotrap® technology for improved quality testing and for the decontamination of animal serum used in cell and tissue culture applications.   According to a 2019 Genetic and Engineering News report, the cell and tissue engineering market generated an estimated $9 billion in product sales in 2017(1).  Because animal serum is a source of many of the required nutrients and growth factors for cell and tissue manufacturing, it is a key supplement added to...

READ MORE
Ceres Nanosciences, University of Virginia, and George Mason University receive $600,000 award from the Virginia Catalyst to develop a Nanotrap® liquid biopsy collection device for cancer diagnostics

MANASSAS, Va. — June 4, 2019 — Ceres Nanosciences, Inc. (Ceres), University of Virginia (UVA), and George Mason University (Mason) today announced the receipt of a $600,000 award from the Virginia Catalyst for the development of a Nanotrap® liquid biopsy collection device. This award will be matched by $1.2 million in product development funding by Ceres Nanosciences. Cancer is the second leading cause of death world-wide and the global cancer burden is expected to grow to 23.6 million new cancer cases by 2030. Tissue biopsies are the current gold standard for detecting and obtaining information about cancer. By collecting cells from tumors, doctors can...

READ MORE
Ceres Nanosciences’ Point-of-Care Nanotrap® Lyme Antigen Test System Granted Breakthrough Device Designation by U.S. Food and Drug Administration.

Manassas, VA – July 12, 2018 – Ceres Nanosciences (Ceres) announced today that is has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its new point-of-care Nanotrap® Lyme Antigen Test System. Under the Breakthrough Device program, formerly the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval. The Ceres’ Nanotrap® Lyme Antigen Test System is a powerful diagnostic test that is intended to be available in point-of-care settings, like a physician’s office or a walk-in clinic. Requiring only a patient’s urine sample, it will...

READ MORE
Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding

Manassas, VA – May 31, 2018 – Ceres Nanosciences (Ceres) is announcing today that it has reached a key product development milestone for its Nanotrap® Lyme Antigen Test System. The Nanotrap® Lyme Antigen Test System will proceed into manufacturing and analytical performance testing this year and is on track for clinical study and FDA submission in 2019. “The Nanotrap® Lyme Antigen Test System presents a unique and powerful approach to dealing with Lyme disease. It will address the critical need for an accurate, direct test for early detection of a devastating disease and it will be available right in the...

READ MORE
Ceres Nanosciences announces plans for significant growth in Prince William County, Virginia

Prince William County, VA – December 12, 2017 – Ceres Nanosciences (Ceres) is pleased to announce its recent expansion in Prince William County, Virginia. Following a successful fundraising round in 2017, Ceres has rapidly expanded both its staff and its facilities to accommodate the growing demand for the novel Nanotrap® particle platform across the life sciences industry. The Nanotrap® particle provides enhanced sample processing capabilities to new and existing diagnostic tests for some of the most challenging diseases and conditions, such as Lyme disease, respiratory diseases, emerging infectious diseases and cancer detection, as well as for improved health and wellness monitoring....

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER